Lataniston

Latanoprost, the active ingredient in Lataniston, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is indicated for the management of open-angle glaucoma and ocular hypertension, where it reduces intra-ocular pressure by enhancing aqueous humor outflow.

GNH USA supplies Lataniston as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality-controlled manufacturing and reliable distribution across global markets. The company adheres to EU regulatory standards and provides comprehensive documentation for import and compliance.

Latanoprost is a prostaglandin analog used in the management of ocular pressure-related conditions.

Open-angle glaucoma: reduces intra-ocular pressure and helps preserve visual field. Ocular hypertension: lowers pressure to prevent progression to glaucoma. Pseudoexfoliative glaucoma: improves aqueous outflow to control intra-ocular pressure.

Latanoprost may cause a range of ocular and peri‑ocular reactions.

Common Side Effects: - Increased iris pigmentation: gradual darkening of the iris color. - Eyelash changes: longer, thicker, or more numerous lashes. - Conjunctival hyperemia: mild eye redness. - Foreign body sensation: feeling of grit or irritation. - Blurred vision: temporary visual disturbance after instillation. - Dry eye: reduced tear production or discomfort.

Serious or Rare Side Effects: - Severe ocular inflammation: intense redness, pain, or swelling. - Allergic reaction: itching, swelling, or rash around the eye. - Macular edema: fluid accumulation in the central retina. - Vision loss: sudden decrease in visual acuity. - Persistent corneal ulcer: non‑healing corneal defect. - Endophthalmitis: intra‑ocular infection requiring urgent care.

Before starting Lataniston, patients should be evaluated for ocular health and potential risk factors.

Monitor intra-ocular pressure: regular measurements after initiation. Assess for iris color change: observe for permanent pigmentation. Check for eyelash changes: note excessive growth or irritation. Avoid use in patients with active ocular infection: postpone treatment until resolved. Pregnancy and lactation: use only if clearly needed after risk assessment. Store at room temperature: keep bottle in original packaging, protect from light and moisture, and discard if opened beyond the recommended period.

Lataniston may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use of other prostaglandin analogues: may increase risk of ocular side effects. - Use with non‑steroidal anti‑inflammatory eye drops: may reduce prostaglandin efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intra‑ocular pressure lowering effect. - Systemic carbonic anhydrase inhibitors: may enhance pressure reduction. - Topical corticosteroids: may increase risk of cataract formation.